Pierre Fabre and Cordeliers Research Centre Enter into strategic partnership to identify new therapeutic targets in immuno-oncology
14 December 2015
Inserm’s Cordeliers Research Centre is internationally recognized for its expertise in immuno-oncology. Pierre Fabre has extensive experience in oncology, priority for its pharmaceutical R&D.
Both partners will work closely together for the next 3 years to identify new biological targets and develop
innovative therapies in immuno-oncology.
The partnership is facilitated by Inserm Transfert, Inserm's structure dedicated to knowledge transfer.
Castres, France, December 14, 2015 – Pierre Fabre Médicament (PFM) announces a strategic partnership with Inserm and its academic partners (Université Paris Descartes-Paris V, Université Pierre et Marie Curie-Paris VI and Université Paris Diderot-Paris
VII) and Inserm Transfert to identify new therapeutic targets in immuno-oncology. Under the terms of this 3-year agreement, Cordeliers Research Center (CRC) and the Center of Immunology Pierre Fabre (CIPF) will work closely to develop tomorrow’s oncological biotherapies. Through periodic collaborative workshops, the CRC teams of Pr. Wolf-Hervé Fridman and CIPF teams will discuss their research and share their expertise in immuno-oncology. This knowledge transfer will combine CRC’s academic scientific excellence and Pierre Fabre’s know-how in the development of biomolecules and in translational medicine, as a way to select patients who might benefit the most from these new targeted treatments.
At first, the CIPF scientists and CRC teams will validate the therapeutic value of the biological targets discovered by the academic researchers. Pierre Fabre teams will bring their expertise in the development of monoclonal antibodies corresponding to these targets. Meanwhile, both entities will work together to identify new therapeutic targets. Academic research will therefore immediately be translated into therapeutic advances adapted to the needs of patients. Meant to bridge the gap between academic and applied research, this partnership aims to provide patients with future immunotherapies against cancer.
Pierre Fabre has extensive experience in oncology and immunology. The CIPF, which focuses on the fight against cancer, specializes in researching targeted biotherapies. Located in Saint-Julien-en-Genevois, it aims at finding monoclonal antibodies used in oncology treatments and the production of biotechnological active substances. Since the creation in 2011 of its Antibodies Biotechnology Unit (ABU), the CIPF is the only French institution to combine applied research, developments and the production of clinical batches, all at the same site. With its translational medicine and clinical oncological expertise, Pierre Fabre is an ideal partner for the development of new therapies in immuno-oncology.
A pioneer of cancer immunology and immunotherapy, the CRC, currently headed by Pr. Pascal Ferré, is internationally recognized for its expertise in these fields. The Center was created in 2007 by Pr. Hervé Fridman, a specialist in clinical immunology, under the joint supervision of Inserm, Université Pierre et Marie Curie, Université Paris Descartes, and Université Paris Diderot-Paris. The research teams of the CRC Department “Cancer, Immunology and Immunopathology” focus on the study of the dialogue between the immune system and cancer, especially within the tumor microenvironment. They are looking into the stress signals induced by different treatments (chemotherapy, antibody therapies) and their impact on the anti-tumor response.
Most of my research has been dedicated to fighting cancer and discovering the best approach to win this fight. By combining our respective expertises, this partnership with Pierre Fabre offers us a unique opportunity to promote the development of our latest discoveries, so that they can become innovative anti-cancer immunotherapies,” welcomed Dr. Wolf-Hervé Fridman.
We are delighted to have concluded this agreement which is key in its duration and ambition. This partnership, at the heart of Inserm’s strategic priorities of innovation, has been signed with a French partner who repeatedly showed in the past its ability to work closely with academic research teams”, said Pascale Augé, CEO, Inserm Transfert.
We are looking forward to implement this strategic partnership in immuno-oncology with such a renowned research center of Inserm. This collaboration will strengthen and increase our ability to develop new targeted biomolecules. This partnership is fully aligned with the Open Innovation strategy that Pierre Fabre Médicament wants to develop” added Nathalie Corvaia, Managing Director of the CIPF.
Pierre Fabre Médicament is deeply committed to the development of new molecules and targeted therapies in oncology, a therapeutic priority for its R&D. This partnership with Inserm will strengthen our internal capabilities to meet not yet covered therapeutic needs in oncology,” commented Dr. Laurent Audoly, Head of Research and Development at Pierre Fabre Médicament.
For more information on Pierre Fabre, please go to www.pierre-fabre.com
Press Contact :
Valérie Roucoules - 01 49 10 83 84